Core Viewpoint - Allarity Therapeutics has reached a final settlement with the U.S. SEC regarding past disclosures related to its New Drug Application for Dovitinib, resolving all regulatory and legal challenges [1][2][3] Settlement Details - The settlement includes a one-time civil penalty of $2.5 million, with Allarity consenting to an administrative cease-and-desist order without admitting or denying the SEC's findings [2][4] - The SEC's investigation found violations of non-scienter-based provisions under Sections 17(a)(2) and (3) of the Securities Act of 1933, as well as Section 13(a) of the Securities Exchange Act of 1934 [2] Company Focus - With the resolution of legal matters, Allarity can now concentrate on advancing its clinical development plans for stenoparib, a dual PARP/Wnt pathway inhibitor [4] - The company has indicated that its cash position is expected to support operations into 2026, and the civil penalty will not affect its financial outlook or clinical programs [4] Product Information - Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential for treating various cancers, including advanced ovarian cancer [5] - Allarity holds exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [5] Company Overview - Allarity Therapeutics is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly through its DRP® technology for companion diagnostics [6]
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission